

Cytiva provides another FlexFactory platform for Chinese biopharma market

28 April 2021 | News

Expanded manufacturing capacity will be used to meet China's current market projections and future global needs



Cytiva, a global life sciences leader, will provide another FlexFactory platform for Chinese biopharmaceutical company, AkesoBio. The 6x2000L space, their third and largest, will be used to further enhance manufacturing capacity of biologics to meet market needs in the country.

China's biopharmaceutical industry is entering a stage of rapid expansion with the market size expecting to reach more than 640 billion yuan by 2023. AkesoBio is spearheading the Chinese biologics market from research to providing commercially approved drugs.

Cytiva partnered with AkesoBio on their first FlexFactory platform in 2016. The project became the first biological agent production facility in Southern China to adopt flexible factory technology with a central control system. It enabled AkesoBio to quickly produce clinical drugs in the shortest production cycle, at a lower operating cost, and gave them the flexibility to quickly switch between various drug candidates. That same year, AkesoBio and Cytiva jointly established the "Southern Antibody Drug Process Development Joint Laboratory" to help AkesoBio achieve efficient process innovation.

In 2019, Cytiva partnered with AkesoBio to produce a 4x2000L FlexFactory platform for the commercial production of AkesoBio research drugs.

Cytiva has over 80 FlexFactory solutions worldwide.